A new randomized trial compared the failure rates of vaginal mesh against hysterectomy with uterosacral ligament suspension for prolapse surgery.
©lenetsnikolai - stock.adobe.com
A new randomized trial suggests that a surgical procedure for uterine prolapse using vaginal mesh is no less likely to fail than hysterectomy with uterosacral ligament suspension. However, no definitive conclusion can be drawn from the results, say the authors, because of a wide confidence interval (CI).
Published in JAMA, the data are from a study at nine clinical sites in the Eunice Kennedy Shriver National Institute of Child Health and Human Development US Pelvic Floor Disorders Network. The participants were postmenopausal women with symptomatic uterovaginal prolapse and enrollment was from April 2013 to February 2015 with 3-year follow-up through February 2018.
The authors aimed to determine whether treatment failure was different for vaginal mesh hysteropexy or vaginal hysterectomy in the women. Failure was based on a composite of retreatment of prolapse, prolapse beyond the hymen, or prolapse symptoms. Secondary outcomes included operative outcomes and adverse events (AEs), which were evaluated with longitudinal models or contingency tables.
Of the 175 women randomized-all of whom were blinded to procedure-88 underwent vaginal mesh hysteropexy and 87 underwent vaginal hysterectomy. After 3-year follow-up, which was completed by 169 of the participants, the authors found that the rate of composite prolapse was not significantly lower in the group that had undergone the mesh procedure. The 36-month adjusted failure incidence was 26% for hysteropexy versus 38% for hysterectomy; adjusted hazard ratio 0.62 (95% CI 0.38-1.02; P = .06). Operative time was shorter in the hysteropexy group (11.5 minutes vs. 43.9 minutes; difference, -45.2 [95% CI, -57.7 to -32.7] P <.001).
AEs in the hysteropexy vs. hysterectomy groups included mesh exposure (8% vs 0%), ureteral kinking managed intraoperatively (0% vs 7%), granulation tissue after 12 weeks (1% vs 11%), and suture exposure after 12 weeks (3% vs 21%). The authors noted that at 3 years, the majority of women in both groups (90% hysteropexy, 89% hysterectomy) reported “much better” or “very much better” improvement on the Patient Global Impression of Improvement (risk difference, 0.00 [95% CI, -0.09 to 0.10]; P = .93). Only the hysterectomy group experienced ureteral “kinking” (7%) and midurethral sling mesh exposure (6%). The rate of mesh exposure in the hysteropexy group was 8%. No reoperations were required for mesh exposures, granulation tissue, or suture exposures.
The authors said their trial “provides new information for failure rate ascertainment” while acknowledging that “the remaining uncertainty is too great to either establish benefit or to rule out the originally hypothesized magnitude of treatment effect.” The women in the study are being followed up for 60 months and the researchers believe that with that extended follow-up, their results and conclusions could change.
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More